{"id":42203,"date":"2026-06-26T21:44:33","date_gmt":"2026-06-26T21:44:33","guid":{"rendered":"https:\/\/www.europesays.com\/france\/42203\/"},"modified":"2026-06-26T21:44:33","modified_gmt":"2026-06-26T21:44:33","slug":"antitrust-regulators-probe-sanofi-for-allegedly-disparaging-a-rival-flu-vaccine","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/france\/42203\/","title":{"rendered":"Antitrust regulators probe Sanofi for allegedly disparaging a rival flu vaccine"},"content":{"rendered":"<p class=\"author-bio\">Ed\u2019s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning <a href=\"https:\/\/www.statnews.com\/signup\/pharmalittle\/\" rel=\"nofollow noopener\" target=\"_blank\">Pharmalittle newsletter<\/a> and the afternoon <a href=\"https:\/\/www.statnews.com\/signup\/pharmalot\/\" rel=\"nofollow noopener\" target=\"_blank\">Pharmalot newsletter<\/a>.<\/p>\n<p>The European Commission is investigating Sanofi for allegedly breaching antitrust rules by running a \u201cmisleading\u201d campaign that disparages the only rival flu vaccine recommended for vulnerable patients at risk for developing the illness.<\/p>\n<p>In explaining its move, the EC maintained that Sanofi portrayed the Fluad vaccine marketed by CSL Seqirus as inferior to its own Efluelda vaccine in a communication campaign that primarily targeted health care professionals in Germany and France. Sanofi holds a dominant position in both countries, according to the EC.<\/p>\n<p>Specifically, the campaign, which also purportedly contradicted national vaccine recommendations in several EU member states, suggested the evidence for using the CSL vaccine was weaker than for using the Sanofi vaccine. The Sanofi shot is specifically designed to provide greater protection against influenza for people over 60 years old.<\/p>\n<p class=\"restricted-text\">STAT+ Exclusive Story<\/p>\n<p class=\"restricted-login\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t<img decoding=\"async\" class=\"restricted-content-breaker-bg\" src=\"https:\/\/www.europesays.com\/france\/wp-content\/uploads\/2026\/05\/stat-plus-breaker-bg.png\" alt=\"STAT+\"\/><\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n\t\t\t\t\t\t<img decoding=\"async\" class=\"stat-plus-logo\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\" alt=\"STAT+\"\/><br \/>\n\t\t\t\t\t<\/a><\/p>\n<p>\t\t\t\tThis article is exclusive to STAT+ subscribers<br \/>\n\t\t\t\tUnlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/p>\n<p class=\"restricted-content-breaker-wrapper-cta mobile\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta mobile\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t\t\t\tIndividual plans<\/p>\n<p>\t\t\t\t\t\tGroup plans<\/p>\n<p>\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button view-all\" data-stat-paywall-cta=\"breaker view all plans\" aria-label=\"View All Plans\" rel=\"nofollow noopener\" target=\"_blank\">View All Plans<\/a><\/p>\n<p class=\"restricted-content-text\">\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button restricted-button\" data-stat-paywall-cta=\"breaker subscribe cta 1\" rel=\"nofollow noopener\" target=\"_blank\">Subscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Ed\u2019s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He&hellip;\n","protected":false},"author":2,"featured_media":42204,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12983],"tags":[13845,73,15202,7437,10105,13012,13378],"class_list":["post-42203","post","type-post","status-publish","format-standard","has-post-thumbnail","category-sanofi","tag-biotechnology","tag-europe","tag-pharmaceuticals","tag-policy","tag-public-health","tag-sanofi","tag-stat"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/posts\/42203","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/comments?post=42203"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/posts\/42203\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/media\/42204"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/media?parent=42203"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/categories?post=42203"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/tags?post=42203"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}